Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

Несбывшиеся надежды и парадоксы профилактической кардиологии

Полный текст:

Аннотация

.

Об авторе

Р. Г. Оганов
Государственный научно-исследовательский центр профилактической медицины Росмедтехнологии
Россия

Директор

Москва



Список литературы

1. Болезни сердца. Ред. Р.Г.Оганов, И.Е.Фомина. Москва “Литтерра” 2006.

2. Ford ES, Ajani UA, Croft JB, et al. Explaining the disease in U.S. deaths from coronary heart disease, 1980-2000. N Engl J Med 2007; 356: 2388-98.

3. Pischon T, Boeing H, Hoffman K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359: 2105-20.

4. Canoy D, Bockholdt SM, Wareham N, et al. Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation into Cancer and Nutrition in Norflock cohort: a population-based prospective study. Circulation 2007; 116: 2933-43.

5. Mc Gee DL. Body mass index and mortality: a meta-analysis based on person-level data from twenty six observational studies. Ann Epidemiol 2005; 15: 87-97.

6. Гундаров И.А., Матвеева С.В. Недостаточная масса тела как фактор риска смерти от сердечно-сосудистых заболеваний. Тер архив 2000; 1: 72-4.

7. Romero-Corral A, Montori YM, Somers VK, et al. Association of body weight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006; 368: 666-78.

8. Uretsky S, Messerli FH, Bangalore S, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 2007; 120: 863-70.

9. Buettner HJ, Mueller C, Gick M, et al. The impact of obesity on mortality in UA/non-ST-segment elevation myocardial infarction. Eur Heart J 2007; 28: 1694-701.

10. Flegal KM, Graubard BI, Williamson DK, Gail MN. Excess deaths associated underweight, overweight and obesity. JAMA 2005; 293: 1861-7.

11. Kelly RV, Hsu A, Topol E, Steinhubl S. The influence of body mass index on outcomes and benefit of antiplatelet therapy following percutaneous coronary intervention. J Invasive Cardiol 2006; 18: 115-9.

12. Mak KH, Bhatt M, Shao M et al. The influence of body mass index on mortality and bleeding among patients with or at high risk of artherothombotic disease. Eur Heart J 2009; 30: 857-65.

13. Andreotti F, Rio T, Lavorgna A. Body fat and cardiovascular risk: understanding the obesity paradox. Eur Heart J 2009; 30: 752-4.

14. Fonarow GC, Abraham WT, Albert NM, et al. A smokers paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. Eur Heart J 2008; 29: 1983-91.

15. He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES 1 epidemiologic follow up study. Arch Intern Med 2001; 161: 996-1002.

16. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006; 27: 65-75.

17. Kelly TL, Gilpin E, Ahnve E, et al. Smoking status at the time of acute myocardial infarction and subsequent prognosis. Am Heart J 1985; 110: 535-41.

18. Barbash GI, Reiner J, White HD, et al. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infraction: mechanism of the “smoking paradox” from the GUSTO-I trial with angiographic insights. JACC 1995; 26: 1222-9.

19. Hasadi D, Lerman A, Rihal ES, et al. Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction. Am Heart J 1999; 137: 612-20.

20. Ovbiagele B, Saver JL. The smoking-thrombolysis paradox and acute ischemic stroke. Neurology 2005; 65: 293-5. 21. Suskin N, Pipe A, Prior P. Smokers paradox or not in heart failure, just quit. Eur Heart J 2008; 29:1932-3.

21. Ланкин В.З., Тихазе А.К., Беленков Ю.Н. Свободнорадикальные процессы при заболеваниях сердечно-сосудистой системы. Кардиология 2000; 7: 48-61.

22. Koh KK, Oh PC, Quon M. Does reversal of oxidative stress and inflammation provide vascular protection. Cardiovasc Res 2009; 81: 649-59.

23. Lonn E, Bosch J, Yusuf E, et al. HOPE HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293: 1338-47.

24. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in primary prevention of cardiovascular disease and cancer: the Women’ Health Study: a randomized controlled trial. JAMA 2005; 294: 56-65.

25. Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta-carotene in the secondary prevention of cardiovascular events in women: results from the Women’ Antioxidant Cardiovascular Study. Arch Intern Med 2007; 167: 1610-8.

26. Sesso HD, Buring JE, Christen WG, et al. Vitamin E and C in the prevention of cardiovascular disease in men: the Physicians’ Health study II randomized controlled trial. JAMA 2008; 300: 2123-33.

27. Грацианский Н.А. Очередное (окончательное?) подтверждение неэффективности антиоксидантных витаминов в профилактике коронарной болезни сердца и ее осложнений. Кардиология 2002; 2: 85-6.

28. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and therisk of cardiovascular disease. N Engl J Med 1996; 335: 453-61.

29. Sarrel PM. Cardiovascular disease in women: implication of hormone replacement therapy. Int J Fert Menopausal Stud 1996; 41: 90-3.

30. Bath P, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005; 330: 432.

31. Beral V, Banks E, Reeves G. Evidence from randomized trials on long-term effects of hormone replacement therapy. Lancet 2002; 360: 942-4.

32. Peverill R. Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab 3002; 17: 149-64.

33. Barrett-Conor E, Wenger NK, Grady D, et al. Coronary heart disease in women, randomized clinical trials, HERS and RUTH. Maturitas 1998; 31: 1-7.

34. Halley S, Grudy D, Bush T, et al. for the Heart and Estrogen/ Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.

35. Грацианский Н.А. Если и существуют показания для применения гормональной заместительной терапии эстрогенами, то предупреждение КБС в их число пока не входит. Кардиология 2000; 6: 23.

36. Sare GM, Gray LJ, Bath MW. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008; 29: 2031-41.

37. Hankey G, Eikelboom. Homocysteine and vascular disease. Lancet 1999; 354: 407-12.

38. Stampfer MJ, Malinow R, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-81.

39. Wald NJ, Watt HC, Law MR, et al. Homocysteine and ischemic heart disease: results of prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862-7.

40. Arnesen E, Refsum H, Bonaa KJ, et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704-9.

41. Pery IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middleaged British men. Lancet 1995; 346: 1395-8.

42. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.

43. Graham IM, Daly LE, Refsum H, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 1997; 277: 1775-81.

44. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor of venous thromboembolic disease. Arch Intern Med 1998; 158: 2101-16.

45. Yang Q, Botto LD, Erickson JD, et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 2006; 113: 1335-43.

46. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death: the Vitamin Intervention for Stroke Prevention (VISP). JAMA 2004; 291: 565-75.

47. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infraction. N Engl J Med 2006; 354: 1578-88.

48. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-77.

49. Antoniades C, Antonopoulos AS, Tousoulis D, et al. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J 2009; 30: 6-15.

50. Wong ND, Ridker PM. Thrombosis, inflammation and infection in Preventive Cardiology. Mc Graw-Hill Health Profession Division. USA 2000.

51. Gurfinkel E, Bozovich G, Daroca A, et al. Randomized trial of roxithromycin in non Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997; 350: 404-7.

52. Kaski YC. ACES и PROVE-IT: гибель инфекционной гипотезы атеросклероза. Европейский кардиологический журнал по факсу. 20/01/05, vol. X, N6.


Для цитирования:


Оганов Р.Г. Несбывшиеся надежды и парадоксы профилактической кардиологии. Кардиоваскулярная терапия и профилактика. 2009;8(7):4-9.

For citation:


Oganov R.G. Failed expectations and paradoxes of preventive cardiology. Cardiovascular Therapy and Prevention. 2009;8(7):4-9. (In Russ.)

Просмотров: 22


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)